Poster Session (Monday, 28 September) Gynaecological Cancer Poster| Volume 51, SUPPLEMENT 3, S548, September 2015

2754 First interim analysis of OTILIA, a large German non-interventional study evaluating front-line bevacizumab (BEV)-containing therapy in patients with ovarian cancer (OC)

      This paper is only available as a PDF. To read, Please Download here.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect